Abstract: The inventors have found that compounds of formula (I) have an effect to protect cartilage. Accordingly the disclosure provides a pharmaceutical composition for protecting cartilage comprising a compound of formula (I) or an ester, oxide, pharmaceutically acceptable salt, or solvate thereof. The pharmaceutical composition can be used for treating and/or preventing a disease associated with cartilage degeneration such as osteoarthritis.

Abstract: The inventors have found that VCP inhibitors protect corneal endothelial cells and corneal epithelial cells. Accordingly, the disclosure provides a composition for protecting a cornea comprising a compound of formula (I) or an ester, oxide, pharmaceutically acceptable salt or solvate thereof. In another aspect the disclosure provides a composition for treating and/or preventing a corneal disease comprising a compound of formula (I). In a further aspect the disclosure provides a composition for ocular irrigation comprising a compound of formula (I). In a still further aspect the disclosure provides a composition for preserving a corneal graft comprising a compound of formula (I).

Abstract: The present invention provides a pharmaceutical composition for removing drusen, suppressing formation of drusen, and/or treating and/or preventing age-related macular degeneration comprising the compound of formula (I) wherein Ra is independently selected from the group consisting of halo, hydroxy, alkyl, halo-substituted alkyl, aryl, halo- or alkyl-substituted aryl, alkoxy, hydroxy- or carboxy-substituted alkoxy, aryloxy, halo- or alkyl-substituted aryloxy, CHO, C(O)-alkyl, C(O)-aryl, C(O)-alkyl-carboxyl, C(O)-alkylene-carboxy ester and cyano, and m is an integer selected from 0 to 4.

Abstract: The present invention provides a pharmaceutical composition for removing drusen, suppressing formation of drusen, and/or treating and/or preventing age-related macular degeneration comprising the compound of formula (I) wherein Ra is independently selected from the group consisting of halo, hydroxy, alkyl, halo-substituted alkyl, aryl, halo- or alkyl-substituted aryl, alkoxy, hydroxy- or carboxy-substituted alkoxy, aryloxy, halo- or alkyl-substituted aryloxy, CHO, C(O)-alkyl, C(O)-aryl, C(O)-alkyl-carboxyl, C(O)-alkylene-carboxy ester and cyano, and m is an integer selected from 0 to 4.

Abstract: The present invention provides agents effective to treat eye diseases, pharmaceutical compositions comprising them, methods for preparing pharmaceuticals for treatment of eye diseases comprising using the agents, use of the agents in manufacture of pharmaceuticals for treatment of eye diseases and methods for treating eye diseases comprising administering the agents or the pharmaceutical compositions. The eye diseases treated by the present invention include particularly glaucoma, especially normal tension glaucoma, or retinitis pigmentosa. The present invention provides the compound of formula (I) wherein R is as defined in the description.

Abstract: The present invention provides a method of producing primate retinal progenitor cells, comprising culturing primate embryonic stem cells as suspended aggregates in a serum-free medium, and obtaining retinal progenitor cells from the culture. The present invention further provides a method of producing photoreceptor precursor cells, comprising culturing isolated retinal progenitor cells differentiated from embryonic stem cells, under adhesive conditions, in the presence of a gamma secretase inhibitor, and obtaining a photoreceptor precursor from the culture.

Abstract: The present invention provides agents effective to treat eye diseases, pharmaceutical compositions comprising them, methods for preparing pharmaceuticals for treatment of eye diseases comprising using the agents, use of the agents in manufacture of pharmaceuticals for treatment of eye diseases and methods for treating eye diseases comprising administering the agents or the pharmaceutical compositions. The eye diseases treated by the present invention include particularly glaucoma, especially normal tension glaucoma, or retinitis pigmentosa. The present invention provides the compound of formula (I) wherein R is as defined in the description.

Abstract: Provided is an adhesive sheet having an adhesive layer formed of an adhesive composition that contains 100 parts by mass of a polyisobutylene-based resin (A) having a weight-average molecular weight of from 270,000 to 480,000, from 5 to 55 parts by mass of a polyisobutylene-based resin (B) having a weight-average molecular weight of from 100,000 to 250,000, and from 10 to 55 parts by mass of a hydrogenated petroleum resin (C) having a softening point of from 90 to 135° C.; and provided is an adhesive sheet having at least one adhesive layer wherein the probe tack of the adhesive layer, as measured at a peel rate of 600 mm/min according to JIS-Z0237 (1991), has two maximum values and wherein the first maximum value P1 detected first is at least 4.0 N and the ratio of the second maximum value P2 detected secondarily to the first maximum value P1 [P2/P1] is from 0.25 to 1.50.

Abstract: The present invention provides a method of producing primate retinal progenitor cells, comprising culturing primate embryonic stem cells as suspended aggregates in a serum-free medium, and obtaining retinal progenitor cells from the culture. The present invention further provides a method of producing photoreceptor precursor cells, comprising culturing isolated retinal progenitor cells differentiated from embryonic stem cells, under adhesive conditions, in the presence of a gamma secretase inhibitor, and obtaining a photoreceptor precursor from the culture.